Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL® (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured.
"We believe the approval of an additional suite to manufacture EXPAREL marks an important milestone for the company," said Dave Stack, president, chief executive officer and chairman of Pacira. "Expansion of our manufacturing capacity will enable us to meet the growing demands of both existing and future customers seeking an EXPAREL-based multimodal pain management regimen to reduce the use of narcotics, with the ultimate goal of decreasing narcotic-related adverse events."
Southwest Research Institute breaks ground on new clinical supply facility